Prosecution Insights
Last updated: November 12, 2026

Gsk Consumer Healthcare Sarl

Technology area: Biotechnology & Pharmaceuticals

3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready

Analysis

Gsk Consumer Healthcare Sarl has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners and 3 distinct art units, showing a distributed prosecution profile across separate technical assignments.

MEYERS, ELIZABETH ANNE is the busiest examiner, with 1 pending matter. The available data does not indicate examiner concentration. Counsel should manage each action independently, while preserving consistent positions on the relevant healthcare, pharmaceutical, and biotechnology terminology throughout the active portfolio.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

3
Total Pending OAs
2
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (67%)
1
Medium (33%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (33%)
Multi-statute (no §101)2 (67%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

3
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

30 h
Manual time on pending OAs
6 h
Time saved (low, 20%)
10 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SANCHEZ, JUSTIN CHRISTOPHER 1 87.3% +12.1%
MEYERS, ELIZABETH ANNE 1 21.1% +93.8%
LAU, JONATHAN S 1 63.8% -17.1%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18570393 NANO-COMPLEX COMPOSITION COMPRISING DICLOFENAC SANCHEZ, JUSTIN CHRISTOPHER —

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18570372 MICELLAR SOLUTION COMPRISING DICLOFENAC MEYERS, ELIZABETH ANNE 58d overdue
18002666 ANTIVIRAL PHARMACEUTICAL COMPOSITION LAU, JONATHAN S —

Interview Candidates (2)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18570372 MICELLAR SOLUTION COMPRISING DICLOFENAC MEYERS, ELIZABETH ANNE 58d overdue
18570393 NANO-COMPLEX COMPOSITION COMPRISING DICLOFENAC SANCHEZ, JUSTIN CHRISTOPHER —

Top Art Units

Art UnitApps
1622 1
1617 1
1693 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18570393 NANO-COMPLEX COMPOSITION COMPRISING DICLOFENAC SANCHEZ, JUSTIN CHRISTOPHER 1622 §103 Non-Final OA — Pending Dec 14, 2023
18570372 MICELLAR SOLUTION COMPRISING DICLOFENAC MEYERS, ELIZABETH ANNE 1617 §103§112 Final Rejection 58d overdue Pending Dec 14, 2023
18002666 ANTIVIRAL PHARMACEUTICAL COMPOSITION LAU, JONATHAN S 1693 §102§103§112 Non-Final OA — Pending Dec 21, 2022

Managing Gsk Consumer Healthcare Sarl's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Gsk Consumer Healthcare Sarl have?

Gsk Consumer Healthcare Sarl has 3 pending office actions as of November 2026, spread across 3 art units and 3 examiners.

Which USPTO examiner handles the most Gsk Consumer Healthcare Sarl applications?

Justin Christopher Sanchez has the most, with 1 of Gsk Consumer Healthcare Sarl's pending office actions.

What technology area are Gsk Consumer Healthcare Sarl's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month